The month of October ended with three Vanderbilt technologies earning patent protection from the USPTO. The most recent patent awarded was for a compound that may help treat major depressive disorder and other neurological disorders. It was developed at the Vanderbilt Center for Neuroscience Drug Discovery by VCNDD Director P. Jeffrey Conn, Craig Lindsley, Kyle Emmitte, David Weaver, Alice Rodriguez, Andrew Felts, Carrie Jones, and Brittney Bates.
Also earning patent protection was an innovative collection station for various lab animal specimens that was developed by Elena Tchekneva and Veronika Kadkina in Vanderbilt’s Nephrology Division, Dina Polosukhina in the Moses Lab at Vanderbilt.
Rounding out the trio of newly awarded patents was an apparatus that combines Raman Spectroscopy and Optical Coherence Tomography to provide simultaneous biochemical and microstructural information about tissue of interest. Vanderbilt researchers who developed this apparatus include Chetan A. Patil and Anita Mahadevan-Jansen in the Department of Biomedical Engineering.
Read more about each technology below.
- 8,569,308 Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
- 8,561,574 Collection station for accelerated collection of specimens from laboratory animals
- 8,553,219 Common detector for combined raman spectroscopy-optical coherence tomography